Topiroxostat is a selective xanthine oxidoreductase (XOR) inhibitor for the management of
hyperuricemia in patients with or without gout. In this work, we aim to employ the …

Febuxostat is recommended by the American College of Rheumatology Gout Management
Guidelines as a first‐line therapy for lowering the level of urate in patients with gout. At …

This study aimed to investigate the pharmacokinetic and pharmacodynamic (PK/PD) profiles
of dotinurad, a novel uricosuric agent, and to construct a PK/PD model to predict serum urate …

Background SIM0295, a novel inhibitor of human uric acid transporter 1 (hURAT1), is used
to treat patients with gout and hyperuricemia. This study aimed to develop population …

Verinurad, a uric acid transporter 1 (URAT1) inhibitor, lowers serum uric acid by promoting
its urinary excretion. Co-administration with a xanthine oxidase inhibitor (XOI) to …

Xanthine oxidase (XO) inhibitors are widely used in the control of serum uric acid levels in
the clinical management of gout. Our continuous efforts in searching novel amide-based XO …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Response to allopurinol in patients
with gout is often suboptimal due to large variability in pharmacokinetics.• The sources of the …

Fexuprazan is a new drug candidate in the potassium-competitive acid blocker (P-CAB)
family. As proton pump inhibitors (PPIs), P-CABs inhibit gastric acid secretion and can be …

Xanthine oxidoreductase (XOR) inhibitors, allopurinol, febuxostat, and topiroxostat are
hyperuricemia and gout therapeutic drugs, which were supposed to be same. However, it …

We aimed to investigate the effect of induced hepatic and renal failure on the
pharmacokinetics of topiramate (TPM) in rats. Twenty-four Sprague-Dawley rats were used …